MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Predictive Oncology Income Statement 2011-2025 | POAI
Annual Income Statement Predictive Oncology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
8.29 M | 10.2 M | 1.22 M | 48.3 M | 12.4 M | 7.46 M | 13.5 M | 5.47 M | 6.47 M | 12 M | 12 M | 47.4 M | - | - |
Shares |
5.45 M | 4.01 M | 3.69 M | 54.9 M | 12 M | 2.87 M | 1.28 M | 636 K | 282 K | 15.5 K | 12 K | 10 K | - | - |
Historical Prices |
1.52 | 2.55 | 0.33 | 0.881 | 1.04 | 2.45 | 10.9 | 13.6 | 22.5 | 750 | 1.24 K | 4.5 K | 1.56 K | 3.09 K |
Net Income |
-12.7 M | -14 M | -25.7 M | -19.7 M | -25.9 M | -19.4 M | -10.1 M | -7.75 M | -6.53 M | -4.79 M | -6.83 M | -9.41 M | -7.42 M | -4.49 M |
Revenue |
1.62 M | 1.63 M | 1.51 M | 1.42 M | 1.25 M | 1.41 M | 1.41 M | 655 K | 456 K | 654 K | 952 K | 468 K | 189 K | 96.6 K |
Cost of Revenue |
826 K | 609 K | 505 K | 487 K | 447 K | 532 K | 416 K | 148 K | - | - | - | - | - | - |
Gross Profit |
798 K | 1.02 M | 1 M | 934 K | 805 K | 880 K | 996 K | 507 K | 275 K | 350 K | 566 K | 278 K | 60.2 K | 40.6 K |
Operating Income |
-10.9 M | -12.1 M | -26 M | -20.4 M | -25.4 M | -22.6 M | -7.86 M | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | 3 | 391 K | 378 K | 637 K | 259 K | 230 K |
EBITDA |
-10.8 M | -11.9 M | -24.7 M | -19.1 M | -24.9 M | -13.1 M | -7.71 M | -7.68 M | -6.44 M | -4.32 M | -6.4 M | -8.78 M | -7.16 M | -4.1 M |
Operating Expenses |
11.7 M | 13.1 M | 27 M | - | 10.9 M | 14.7 M | 8.86 M | 8.25 M | 6.8 M | 4.75 M | 7.03 M | 9.21 M | 7.22 M | 4.15 M |
General and Administrative Expenses |
7.42 M | 8.38 M | 11.1 M | 10.9 M | 10.4 M | 9.78 M | 4.63 M | 7.25 M | 5.17 M | 4.25 M | 5.86 M | 8.63 M | 7.05 M | 3.91 M |
All numbers in USD currency
Quarterly Income Statement Predictive Oncology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
724 K | 9.11 M | 7.15 M | 444 K | 426 K | 4.66 M | 4.06 M | 4.06 M | 4.03 M | 4 M | 3.97 M | 3.94 M | 3.92 M | 3.59 M | 3.29 M | 65.6 M | 65.4 M | 51.6 M | 36.5 M | 19.8 M | 15 M | 9.84 M | 4.89 M | 4.06 M | 3.15 M | 2.96 M | 1.57 M | 1.41 M | 1.33 M | 11.9 M | 11.4 M | 6.94 M | 6.23 M | 6.17 M | 6.45 M | 4.56 M | 3.32 M | 2.7 M | 724 K | 208 K | 157 K | 3.26 M | 3.1 M | 3.09 M | 2.98 M | 2.97 M | 2.95 M | 2.93 M | 1.82 M | 121 M | 108 M | 104 M | 79.5 M | 54.7 M | 32.7 M | 32.1 M | 16.6 M | 16.6 M | 32.1 M |
Net Income |
-77.7 M | -2.07 M | -2.44 M | - | -3.09 M | -3.18 M | -4.22 M | - | -3.16 M | -3.92 M | -3.42 M | - | -4.06 M | -10.4 M | -3.37 M | - | -5.44 M | -2.57 M | -3.89 M | - | -6.31 M | -3.58 M | -4.53 M | - | -4.01 M | 1.47 M | -3.29 M | - | -2.51 M | -2.37 M | -1.76 M | - | -992 K | -2.54 M | -7.75 M | - | -6.53 M | -6.53 M | -6.53 M | - | -4.79 M | -1.19 M | -226 K | - | -1.12 M | -1.74 M | -1.62 M | - | -3.97 M | -1.18 M | -2.1 M | - | -2.86 M | -2.14 M | -713 K | - | -477 K | -477 K | -4.49 M |
Revenue |
3.62 K | 2.68 K | 110 K | - | 3.91 K | 67.3 K | 4.86 K | - | 677 K | 490 K | 240 K | - | 456 K | 372 K | 315 K | - | 314 K | 350 K | 280 K | - | 481 K | 183 K | 295 K | - | -440 K | -440 K | -440 K | - | -646 K | -961 K | 412 K | - | 153 K | 107 K | 175 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
8.36 K | 18.2 K | 45.1 K | - | 11.2 K | 13.9 K | 22.4 K | - | 97.9 K | 160 K | 120 K | - | 108 K | 134 K | 109 K | - | 110 K | 143 K | 97.8 K | - | 175 K | 85.3 K | 92.7 K | - | 208 K | 118 K | 73.7 K | - | 83 K | 109 K | 117 K | - | 28.7 K | 22 K | 37 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
-4.74 K | -15.5 K | 65.2 K | - | -7.27 K | 53.4 K | -17.6 K | - | 579 K | 330 K | 120 K | - | 348 K | 238 K | 205 K | - | 203 K | 207 K | 183 K | - | 306 K | 97.5 K | 202 K | - | 315 K | 168 K | 182 K | - | 247 K | 250 K | 294 K | - | 124 K | 84.8 K | 138 K | - | 108 K | 48.7 K | 11 K | - | 66 K | 150 K | 55.3 K | - | 263 K | 220 K | 39.1 K | - | 81.7 K | 83.5 K | 83.5 K | - | -18.3 K | 23.2 K | 8.83 K | - | 9.1 K | 554 | - |
Operating Income |
-3.28 M | -2.66 M | -2.29 M | - | -2.16 M | -2.46 M | -3.58 M | - | -2.74 M | -3.96 M | -3.46 M | - | -4.13 M | -10.5 M | -3.41 M | - | -5.49 M | -2.6 M | -3.78 M | - | -5.61 M | -3.77 M | -3.44 M | - | -3.44 M | -5.1 M | -2.34 M | - | -1.86 M | -1.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.22 K | - | - | - | - | - | - | - | - | - | - | 3 | - | - | - | 51.8 K | 189 K | 154 K | - | 132 K | 14.8 K | 18.1 K | - | 408 K | 127 K | 95.6 K | - | 23.7 K | 89.3 K | 55.5 K | - | 61 K | 57.9 K | 57.9 K |
EBITDA |
-3.25 M | -2.63 M | -2.25 M | - | -2.13 M | -2.43 M | -3.55 M | - | -2.7 M | -3.78 M | -3.23 M | - | -3.9 M | -10.3 M | -3.09 M | - | -4.52 M | -1.95 M | -3.46 M | - | -4.89 M | -3.37 M | -3.23 M | - | -2.96 M | -4.84 M | -2.3 M | - | -1.76 M | -1.37 M | 18.2 K | - | 53.8 K | 36 K | 18.6 K | - | 62.4 K | 42.1 K | 21 K | - | 57.5 K | 39 K | 19.9 K | - | 44.1 K | 25.8 K | 9.38 K | - | 156 K | 141 K | 311 | - | 768 | 457 | 147 | - | 1.82 K | 1.21 K | 607 |
Operating Expenses |
3.28 M | 2.64 M | 2.35 M | - | 2.15 M | 2.52 M | 3.56 M | - | 3.32 M | 4.29 M | 3.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.34 M | - | - | - | 1.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.61 M | 1.88 M | 1.83 M | - | 1.55 M | 1.83 M | 2.33 M | - | 2.34 M | 2.7 M | 2.34 M | - | 3.29 M | 2.35 M | 2.42 M | - | 2.06 M | 2.08 M | 3.27 M | - | 2.23 M | 3.21 M | 2.83 M | - | 2.62 M | 3.31 M | 1.5 M | - | 763 K | 730 K | 1.24 M | - | 622 K | 2.21 M | 1.13 M | - | 733 K | 2.26 M | 1.69 M | - | 861 K | 856 K | -128 K | - | 738 K | 1.33 M | 1.18 M | - | 3.2 M | 888 K | 888 K | - | 2.52 M | 1.95 M | 566 K | - | 429 K | 273 K | 313 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Predictive Oncology (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Baxter International
BAX
|
$ 19.11 | 0.95 % | $ 9.75 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 196.12 | 0.23 % | $ 56.4 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 5.47 | 3.01 % | $ 110 M | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 175.8 | -1.49 % | $ 5.48 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.73 | 0.64 % | $ 31 M | USA |
 |
Repro Med Systems
KRMD
|
$ 6.48 | -0.61 % | $ 295 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 84.34 | 0.44 % | $ 1.89 B | USA |
 |
ICU Medical
ICUI
|
$ 146.98 | -0.35 % | $ 3.58 B | USA |
 |
Alcon
ALC
|
$ 80.17 | 0.06 % | $ 40.4 B |  Schweiz |
 |
Merit Medical Systems
MMSI
|
$ 87.39 | -0.27 % | $ 5.09 B | USA |
 |
AtriCure
ATRC
|
$ 40.55 | 0.02 % | $ 1.9 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
electroCore
ECOR
|
$ 4.86 | 1.25 % | $ 26.8 K | USA |
 |
AngioDynamics
ANGO
|
$ 13.16 | - | $ 538 M | USA |
 |
The Cooper Companies
COO
|
$ 82.57 | -0.37 % | $ 16.4 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 116.64 | 0.4 % | $ 5.65 B | USA |
 |
Masimo Corporation
MASI
|
$ 133.28 | -0.44 % | $ 7.1 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 80.01 | -0.44 % | $ 4.03 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.11 | 0.66 % | $ 188 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 577.15 | -0.03 % | $ 205 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.43 | 2.53 % | $ 181 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.18 | - | $ 22.2 M |  Israel |
 |
STERIS plc
STE
|
$ 255.68 | 0.11 % | $ 25.2 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | -0.48 % | $ 23.1 M | USA |
 |
Nephros
NEPH
|
$ 5.23 | 12.23 % | $ 54.3 M | USA |
 |
Stereotaxis
STXS
|
$ 2.43 | -0.82 % | $ 196 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.0 | 0.59 % | $ 3.79 B | USA |
 |
ResMed
RMD
|
$ 244.44 | -0.07 % | $ 35.7 B | USA |
 |
Pro-Dex
PDEX
|
$ 40.4 | -2.38 % | $ 133 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 14.86 | 1.92 % | $ 714 M | USA |
 |
Utah Medical Products
UTMD
|
$ 56.29 | -1.14 % | $ 204 M | USA |
 |
Repligen Corporation
RGEN
|
$ 165.66 | -0.42 % | $ 9.23 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.22 | 1.26 % | $ 2.28 B | USA |
 |
BioLife Solutions
BLFS
|
$ 25.41 | -0.2 % | $ 1.17 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 23.63 | -1.25 % | $ 1.16 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.82 | 0.22 % | $ 24.5 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 122.33 | 0.03 % | $ 5.73 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 276.66 | -0.3 % | $ 20.2 B | USA |